Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1590-3478
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis ; volume:42 ; number:8 ; day:20 ; month:5 ; year:2021 ; pages:3135-3143 ; date:8.2021
Neurological sciences ; 42, Heft 8 (20.5.2021), 3135-3143, 8.2021
- Creator
-
Negida, Ahmed
Ghaith, Hazem S.
Fala, Salma Yousry
Ahmed, Hussien
Bahbah, Eshak I.
Ebada, Mahmoud Ahmed
Aziz, Mohamed Abd Elalem
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10072-021-05319-7
- URN
-
urn:nbn:de:101:1-2021103011102581272859
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Negida, Ahmed
- Ghaith, Hazem S.
- Fala, Salma Yousry
- Ahmed, Hussien
- Bahbah, Eshak I.
- Ebada, Mahmoud Ahmed
- Aziz, Mohamed Abd Elalem
- SpringerLink (Online service)
Other Objects (12)
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis